EmbarkNeuro is a neuroscience-focused biotech portfolio company of Aditum Bio, the biotech investment firm co-founded in 2019 by former Novartis CEO Joe Jimenez and former President of the Novartis Institutes for BioMedical Research (NIBR) Dr. Mark Fishman. EmbarkNeuro has a Phase II asset being evaluated in patients with major depressive disorder. The company was formed following the in-licensing of a selective vasopressin 1b receptor (V1b) antagonist (ANC-501) from Taisho Pharmaceutical Co., Ltd. At EmbarkNeuro, we are: patient-centric, collaborative, curious and courageous.
